Weight Loss Injections Tied to Reduced Dementia and Stroke Risk

New Study Reveals Potential Benefits of Weight Loss Drugs on Dementia and Stroke Risk

A recent study has uncovered potential protective effects of weight loss drugs against dementia and stroke, offering new insights into their broader health benefits. Researchers found that individuals with type 2 diabetes and obesity who take these medications may experience a lower risk of developing these conditions and are less likely to die prematurely.

While the primary use of drugs such as Wegovy and Mounjaro is for managing weight and blood sugar levels, their additional health advantages remain unclear. The study, conducted by experts from Taiwan, analyzed data from 60,000 people worldwide, with an average age of 58, who had type 2 diabetes and obesity.

Half of the participants were given GLP agonist drugs, including semaglutide and tirzepatide, which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient in Ozempic, a drug used for treating type 2 diabetes. These drugs work by reducing appetite, slowing digestion, decreasing the liver's production of sugar, and helping the body produce more insulin when needed.

The other half of the participants received alternative anti-diabetic medications. Over a seven-year follow-up period, those taking GLP agonists showed a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the study period.

Further analysis revealed even greater benefits among specific groups, including individuals aged 60 or older, women, and those with a body mass index (BMI) between 30 and 40. However, no differences were observed in cases of Parkinson’s disease or brain bleeds.

The researchers highlighted that their findings suggest potential neuroprotective and cerebrovascular benefits of these drugs but emphasized the need for further studies to confirm the results. “These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,” they stated in the journal JAMA Network Open.

Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh, noted that this study adds to the growing evidence linking GLP1 receptor agonists with a lower risk of dementia in people with type 2 diabetes and obesity. However, she cautioned that the study cannot determine whether the drugs directly protect the brain. Instead, she suggested that effectively treating diabetes and obesity could reduce dementia and stroke risks, as these conditions are known risk factors.

Dr. Richard Oakley, associate director of research and innovation at Alzheimer’s Society, emphasized that diabetes and obesity are well-established risk factors for dementia. He pointed out that while the study supports existing evidence about the potential of these drugs to reduce dementia risk, especially in older individuals with type 2 diabetes and obesity, it is an observational study. Therefore, conclusions should be drawn cautiously, as only a small number of participants developed dementia, and the impact on different types of dementia remains unclear.

He also mentioned that clinical trials are currently exploring whether these drugs can be used to treat early-stage Alzheimer’s disease, highlighting the importance of continued research in this area. The findings open up exciting possibilities for future studies and potential treatments in the fight against dementia.